Roche scores FDA nod for prefilled syringe version of Vabysmo, easing its administration

Since Roche gained approval for its eye disease medication Vabysmo in 2022, it has stormed a market dominated by Regeneron and Bayer’s Eylea.

Friday, Roche took another step in its advancement of the blockbuster medicine, scoring an FDA nod to provide it in a prefilled syringe. The 6-mg, single-dose shot will give doctors a simplified, ready-to-use alternative to extracting Vabysmo from a vial.